GoodRx Q1 revenue $194M, raises FY2026 guidance; Pharma Direct up 82% YoY

GoodRx Holdings, Inc.

2026-Q1 EPS reported $0.00 revenue$194,006,000

Revenue $194.0M; net income $1.2M; adjusted EBITDA $58.3M (30.0% margin).
Pharma Direct Revenue increased 82% YoY, leading growth momentum.
Company raises full year 2026 revenue and adjusted EBITDA expectations.
Adjusted Net Income $23.0M; Adjusted Net Income Margin 11.9%.
Net cash from operating activities $11.8M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GoodRx Holdings, Inc. reported first quarter of 2026 results: revenue $194.0 million, net income $1.2 million. Guidance raised.

Period: first quarter of 2026
Revenue: $194.0 million
Net income: $1.2 million
Guidance: raised
Result: reported results

Exact text from the filing

the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2026 . First Quarter 2026 Highlights • Revenue of $194.0 million • Net income of $1.2 million ; Net income margin of 0.6% • Adjusted Net Income 1 of $23.0 million ; Adjusted Net Income Margin 1 of 11.9% • Adjusted EBITDA 1 of $58.3 million ;

View on SEC.gov

Browse all earnings releases →

GoodRx Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001809519-26-000110

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.